Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer

Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer

BACKGROUND AND OBJECTIVES: Pemetrexed is a multitargeted folate pathway inhibitor with documented activity in non-small cell lung cancer (NSCLC). The presumed maximum tolerated dose is 500 mg/m2 every 3 weeks, but pemetrexed-related toxicity is ameliorated when folate and B12 supplementation is prov...

Full description

Bibliographic Details
Main Authors: Christos Emmanouilides, Theodora Yermetaki, Anastasia Serpanou, Evdoxia Sapountzi, Polyxeni Mantziari, Iraklis Titopoulos, Dimitrios Filippou
Format: Article
Language:English
Published: Elsevier 2010-01-01
Series:Hematology/Oncology and Stem Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387610500542

Similar Items

Similar Items